Search Results - Keith D. Wilner

Refine Results
  1. 1
    Single‐ and multiple‐dose pharmacokinetics of ziprasidone under non‐fasting conditions in healthy male volunteers

    Single‐ and multiple‐dose pharmacokinetics of ziprasidone under non‐fasting conditions in healthy male volunteers by J. Miceli, Keith D. Wilner, RA Hansen, A. Johnson, Glen Apseloff, Nicolas Gerber

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007)

    Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007) by Sai‐Hong Ignatius Ou, Yiyun Tang, Anna Polli, Keith D. Wilner, Patrick Schnell

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil

    The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil by Gary J. Muirhead, Keith D. Wilner, Wayne A. Colburn, Gertrude Haug‐Pihale, Bernhard Rouviex

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

    CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib by Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D. Wilner

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Treatment of Growing Teratoma Syndrome

    Treatment of Growing Teratoma Syndrome by David J. Vaughn, Keith T. Flaherty, Priti Lal, Maryann Gallagher, Peter J. O’Dwyer, Keith D. Wilner, Isan Chen, Gary K. Schwartz

    Published 2009
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  6. 6
    Rapid Radiographic and Clinical Improvement After Treatment of a <i>MET</i>-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

    Rapid Radiographic and Clinical Improvement After Treatment of a <i>MET</i>-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor by S. Andrew, Tracy T. Batchelor, Eunice L. Kwak, Jeffrey W. Clark, Daphne L. Wang, Keith D. Wilner, David N. Louis, A. John Iafrate

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

    Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced... by Fiona Blackhall, Dong‐Wan Kim, Benjamin Besse, Hiroshi Nokihara, Ji‐Youn Han, Keith D. Wilner, Arlene Reisman, Shrividya Iyer, Vera Hirsh, Alice T. Shaw

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

    Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) by Gary K. Schwartz, P. LoRusso, Mark A. Dickson, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Ronan Courtney, Peter J. O’Dwyer

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

    Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer by Keith T. Flaherty, Patricia LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study by Yaël P. Mossé, Stephan D. Voss, Megan S. Lim, Delphine C.M. Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

    Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer by Makoto Nishio, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Benjamin Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

    Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer by Chandrasekar Durairaj, Ana Ruiz‐García, Eric Gauthier, Xin Huang, Dongrui R. Lu, Justin T. Hoffman, Richard S. Finn, Anil A. Joy, Johannes Ettl, Hope S. Rugo, Jenny Zheng, Keith D. Wilner, Diane D. Wang

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

    First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer by Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

    Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) by Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Complex renal cysts associated with crizotinib treatment

    Complex renal cysts associated with crizotinib treatment by Patrick Schnell, Cynthia Huang Bartlett, Benjamin Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso De Pas, S.D. Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Z. Safferman, Ji‐Youn Han

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer by Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast... by Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

    The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers by Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, James E. Butrynski, Marzia Capelletti, Liping Wang, Nathanael S. Gray, Keith D. Wilner, James G. Christensen, George D. Demetri, Geoffrey I. Shapiro, Scott J. Rodig, Michael J. Eck, Pasi A. Jänne

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating... by Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

    Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer by Sai‐Hong Ignatius Ou, Lyudmila Bazhenova, D. Ross Camidge, Benjamin Solomon, June Herman, Tatiana S. Kain, Yung‐Jue Bang, Eunice L. Kwak, Alice T. Shaw, Ravi Salgia, Robert G. Maki, Jeffrey W. Clark, Keith D. Wilner, A. John Iafrate

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: